Summary
This phase 3a randomised controlled trial (STEP 6) evaluated the efficacy and safety of once-weekly semaglutide in an East Asian population with overweight or obesity, with or without concurrent type 2 diabetes. The trial employed a double-blind, double-dummy design to assess weight loss and metabolic outcomes as primary endpoints. The findings contribute to evidence on GLP-1 receptor agonist effectiveness across diverse ethnic populations, though the record does not detail specific effect magnitudes without access to the full abstract.
UK applicability
Findings from this East Asian-specific trial may inform UK clinical practice regarding semaglutide use in diverse ethnic populations, particularly as the UK has significant Asian communities; however, direct applicability depends on whether baseline characteristics, comorbidities, and genetic factors differ materially from UK cohorts treated in NHS settings.
Key measures
Body weight change, glycaemic endpoints (HbA1c), adverse events, tolerability
Outcomes reported
The study measured weight loss, glycaemic control, and safety outcomes in East Asian adults with overweight or obesity, with or without type 2 diabetes, treated with weekly semaglutide injections versus placebo.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.